NAPSR News: Daiichi-Sankyo will Acquire Ambit Biosciences

PRLog - Sep. 29, 2014 - WASHINGTON, D.C. -- Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S. based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement. Daiichi Sankyo will be acquiring all outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer.

http://ift.tt/1nAjcDQ